Free Trial
NASDAQ:AMGN

Amgen Q2 2025 Earnings Report

Amgen logo
$296.88 +1.78 (+0.60%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$297.50 +0.62 (+0.21%)
As of 08/1/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amgen EPS Results

Actual EPS
N/A
Consensus EPS
$5.21
Beat/Miss
N/A
One Year Ago EPS
N/A

Amgen Revenue Results

Actual Revenue
N/A
Expected Revenue
$8.86 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Amgen Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Tuesday, August 5, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Amgen Earnings Headlines

Amgen (AMGN) Board Declares US$2.38 Dividend for Q3 2025
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
AMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND
See More Amgen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Amgen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Amgen and other key companies, straight to your email.

About Amgen

Amgen (NASDAQ:AMGN) discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

View Amgen Profile

More Earnings Resources from MarketBeat